In a filing, Xilio Therapeutics Inc revealed its Director Shannon James Samuel acquired Company’s shares for reported $30870.0 on Jun 16 ’25. In the deal valued at $0.69 per share,45,000 shares were bought. As a result of this transaction, Shannon James Samuel now holds 45,000 shares worth roughly $31499.999999999996.
Then, Shannon James Samuel bought 25,000 shares, generating $17,215 in total proceeds. Upon buying the shares at $0.69, the Director now owns 70,000 shares.
Before that, Russo Rene bought 36,289 shares. Xilio Therapeutics Inc shares valued at $24,680 were divested by the PRESIDENT AND CEO at a price of $0.68 per share. As a result of the transaction, Russo Rene now holds 281,172 shares, worth roughly $0.2 million.
Chardan Capital Markets initiated its Xilio Therapeutics Inc [XLO] rating to a Buy in a research note published on December 21, 2022; the price target was $7. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Raymond James began covering XLO with “an Outperform” recommendation on November 16, 2021. Morgan Stanley started covering the stock on November 16, 2021. It rated XLO as “an Overweight”.
Price Performance Review of XLO
On Tuesday, Xilio Therapeutics Inc [NASDAQ:XLO] saw its stock jump 0.36% to $0.7. Over the last five days, the stock has lost -1.84%. Xilio Therapeutics Inc shares have fallen nearly -24.30% since the year began. Nevertheless, the stocks have fallen -26.70% over the past one year. While a 52-week high of $1.70 was reached on 02/12/25, a 52-week low of $0.62 was recorded on 04/07/25.
Levels Of Support And Resistance For XLO Stock
The 24-hour chart illustrates a support level at 0.6718, which if violated will result in even more drops to 0.6436. On the upside, there is a resistance level at 0.7183. A further resistance level may holdings at 0.7366.
How much short interest is there in Xilio Therapeutics Inc?
A steep rise in short interest was recorded in Xilio Therapeutics Inc stocks on 2025-06-30, growing by 2.53 million shares to a total of 3.32 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-30 was 0.79 million shares. There was a rise of 76.14%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 16, 2021 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
